Results for

This bill amends the Internal Revenue Code to permit the treatment of certain employer contributions made to public retirement plans as picked up by a governmental employing unit regardless of whether the participating employee is allowed to make an irrevocable election between the application of two alternative benefit formulas involving the same or different levels of employee contributions.

Equal Treatment of Faith-Based Organizations Act of 2020 This bill provides statutory authority for certain restrictions on conditions for financial assistance and program participation imposed by the Department of Health and Human Services (HHS) with respect to faith-based organizations. Specifically, HHS shall not impose specified conditions on faith-based organizations regarding the receipt of HHS funds or the participation in HHS programs, such as requirements to disclose religious affiliation, if those conditions are not imposed on organizations that are not faith-based. In addition, HHS shall not require any organization to refer a beneficiary who objects to the religious character of that organization to an alternative provider. States and local governments that administer HHS funds must adhere to these requirements, as well. Under current law, these restrictions apply to HHS financial assistance and programs through an executive order concerning the administration of federal grants and programs related to faith-based organizations.

Ensuring Vaccination and Treatment Affordability Act This bill requires COVID-19 (i.e., coronavirus disease 2019) vaccines and treatment, as well as treatment for conditions that may complicate COVID-19 treatment, to be covered without cost-sharing under the Children's Health Insurance Program (CHIP) and Medicaid. Additionally, the bill includes vaccines for COVID-19 in the Vaccines for Children (VFC) Program. The VFC Program provides free vaccinations to individuals 18 years of age or younger who are uninsured or underinsured (i.e., with limited or no insurance for vaccines), are eligible for Medicaid, or are American Indians or Alaskan Natives.

Ensuring Treatment for COVID Act This bill requires state Medicaid programs to cover treatment for COVID-19 (i.e., coronavirus disease 2019). State Medicaid programs must also cover COVID-19 testing and treatment for uninsured individuals. (Currently, state Medicaid programs are required to cover COVID-19 testing for enrollees and have the option to cover testing for uninsured individuals.) Coverage must be provided with no cost-sharing. Additionally, state Medicaid programs may not impose cost-sharing for COVID-19 vaccines.

Alternatives to Detention Act of 2019 This bill requires the Department of Homeland Security (DHS) to establish programs for providing alternatives to detaining individuals under the immigration laws, including community-based supervision and community support programs. DHS may not detain and must place in an alternative detention program individuals deemed members of a vulnerable population (e.g., asylum seekers, pregnant or nursing women, or crime victims), a parent of a child under age 18, or a caregiver. DHS shall not use alternative detention programs for (1) aliens subject to mandatory detention, or (2) aliens where release on bond or recognizance is deemed to be sufficient. DHS shall establish the position of Coordinator of Alternatives to Detention and Family Reunification to coordinate the use of alternative detention programs and to reunify parents with children separated from them. Executive departments shall cooperate with the coordinator to the greatest extent practicable to facilitate the performance of the coordinator's mission.

Access to Infertility Treatment and Care Act This bill requires private health insurance plans to cover (1) specified infertility treatments (e.g., in vitro fertilization), if the plan also covers obstetrical services; and (2) fertility preservation services for individuals who undergo medically necessary treatment that may cause impairment of fertility. Private health insurance plans must apply cost sharing for such services that does not exceed the amount for similar services covered by the plan. Further, plans are prohibited from (1) providing incentives for plan holders to forego infertility treatment, or (2) reducing the reimbursement rate to providers of such treatments. The bill also extends infertility treatment and fertility preservation coverage to Medicaid enrollees, federal employees, members of the military, and veterans.

Access to Infertility Treatment and Care Act This bill requires private health insurance plans to cover (1) specified infertility treatments (e.g., in vitro fertilization), if the plan also covers obstetrical services; and (2) fertility preservation services for individuals who undergo medically necessary treatment that may cause impairment of fertility. Private health insurance plans must apply cost sharing for such services that does not exceed the amount for similar services covered by the plan. Further, plans are prohibited from (1) providing incentives for plan holders to forego infertility treatment, or (2) reducing the reimbursement rate to providers of such treatments. The bill also extends infertility treatment and fertility preservation coverage to Medicaid enrollees, federal employees, members of the military, and veterans.

Humane and Existing Alternatives in Research and Testing Sciences Act of 2019or the HEARTS Act of 2019 This bill directs the National Institutes of Health (NIH) to promote nonanimal research methods. Specifically, NIH must (1) provide incentives for nonanimal research and (2) require the evaluation of viable nonanimal methods before approving animal-based research. Additionally, NIH applications for research grants must include (1) harm-benefit analyses for animal-based research proposals and (2) assurance that nonanimal methods for such research are not available.

Alternative Fuel Tax Credit Extension Act of 2019 This bill extends and phases out the tax credit for alternative fuels used as a motor fuel, including compressed, liquefied, and renewable natural gas. It provides for a credit equal to the product of (1) 50 cents and the number of gallons of alternative fuel used in certain vehicles before January 1, 2025, and (2) 25 cents for 2025 through 2026. The credit terminates after 2026. The bill also extends outlay payments of such credit through 2026.

Increase Transportation Alternatives Investment Act of 2019 This bill directs the Department of Transportation (DOT) to ensure that states give preference under the Surface Transportation Block Grant Program to eligible projects that (1) are located in areas that are undergoing extensive repair or reconstruction of transportation infrastructure, including federal-aid highways, federally owned roads open for public travel, passenger rail facilities, and public transportation facilities; and (2) will provide transportation alternatives related to the closure of transportation infrastructure in such areas. DOT shall (1) carry out a competitive grant program to support community efforts to invest in transportation alternatives; and (2) give preference in awarding grants to projects located in such areas. Entities eligible for grants include state and local governments, metropolitan planning organizations, and rural planning organizations.

Transportation Alternatives Enhancements Act This bill revises and reauthorizes the surface transportation block grant program (Transportation Alternatives Program) in the Department of Transportation. States are allowed to allocate funds under the program to counties, metropolitan planning organizations, regional transportation planning organizations, and local governments. Metropolitan planning organizations that serve an urbanized area with a population of 200,000 or fewer are eligible for funding. The bill adjusts the funding limits for states to improve the ability of applicants to access funding in an efficient and expeditious manner.

Lymphedema Treatment Act This bill includes certain lymphedema compression treatment items as covered durable medical equipment under Medicare. (Lymphedema is a condition of localized fluid retention and tissue swelling that is caused when the lymphatic system is damaged or blocked.)

Mainstreaming Addiction Treatment Act of 2019 This bill removes the requirement that a health care practitioner apply for a separate waiver through the Drug Enforcement Administration to dispense certain narcotic drugs (e.g., buprenorphine) for maintenance or detoxification treatment (i.e., substance use disorder treatment). Further, the bill directs the Substance Abuse and Mental Health Services Administration to conduct a national campaign to educate health care practitioners and encourage them to integrate substance use disorder treatment into their practices.

Opioid Treatment Providers Training Act This bill makes certain opioid treatment programs eligible for grants that provide low-income individuals with education and training for health care occupations.

Veteran Treatment Court Coordination Act of 2019 This bill directs the Department of Justice to establish a Veterans Treatment Court Program to provide grants and technical assistance for state, local, and tribal governments to develop and maintain veterans treatment courts.

Veteran Treatment Court Coordination Act of 2019 This bill directs the Department of Justice to establish a Veterans Treatment Court Program to provide grants and technical assistance for state, local, and tribal governments to develop and maintain veterans treatment courts.

Budgeting for Opioid Addiction Treatment Act This bill imposes a one cent per milligram fee on the sale of active opioids by the manufacturer, producer, or importer. The fee excludes prescription drugs used exclusively for the treatment of opioid addiction as part of a medically assisted treatment effort. The Department of Health and Human Services (HHS) must establish a program to provide rebates or discounts to cancer and hospice patients to ensure that they do not pay the fee. Any increase in federal revenues from the fee after rebates and discounts are subtracted must be distributed to states under the Substance Abuse Prevention and Treatment Block Grant program. The states must use the funds exclusively for substance abuse (including opioid abuse) efforts in the states, including (1) specified treatment programs, and (2) the recruitment and training of substance use disorder professionals to work in rural and medically underserved communities. HHS must report to Congress on the impact of this bill on the retail cost of opioids and patient access to opioid medication, the effectiveness of the discount or rebate for cancer and hospice patients, how the funds are being used to improve substance abuse treatment efforts, and suggestions for improving access to opioids for cancer and hospice patients and substance abuse treatment efforts.

Budgeting for Opioid Addiction Treatment Act This bill imposes a one cent per milligram fee on the sale of active opioids by the manufacturer, producer, or importer. The fee excludes prescription drugs used exclusively for the treatment of opioid addiction as part of a medically assisted treatment effort. The Department of Health and Human Services (HHS) must establish a program to provide rebates or discounts to cancer and hospice patients to ensure that they do not pay the fee. Any increase in federal revenues from the fee after rebates and discounts are subtracted must be distributed to states under the Substance Abuse Prevention and Treatment Block Grant program. The states must use the funds exclusively for substance abuse (including opioid abuse) efforts in the states, including (1) specified treatment programs, and (2) the recruitment and training of substance use disorder professionals to work in rural and medically underserved communities. HHS must report to Congress on the impact of this bill on the retail cost of opioids and patient access to opioid medication, the effectiveness of the discount or rebate for cancer and hospice patients, how the funds are being used to improve substance abuse treatment efforts, and suggestions for improving access to opioids for cancer and hospice patients and substance abuse treatment efforts.

Treatment Family Care Services Act This bill requires the Department of Health and Human Services (HHS) to issue guidance outlining opportunities for states to fund treatment family care services through Medicaid, the Payments for Foster Care and Permanency program, or other HHS programs. Treatment family care services are structured, daily emotional and behavioral services and interventions provided in a home-based setting for children less than 21 years old. Additionally, HHS must develop and issue guidance about best practices for states to establish treatment family care services programs.

Treatment Family Care Services Act This bill requires the Department of Health and Human Services (HHS) to issue guidance outlining opportunities for states to fund treatment family care services through Medicaid, the Payments for Foster Care and Permanency program, or other HHS programs. Treatment family care services are structured, daily emotional and behavioral services and interventions provided in a home-based setting for children less than 21 years old. Additionally, HHS must develop and issue guidance about best practices for states to establish treatment family care services programs.

Mainstreaming Addiction Treatment Act of 2019 This bill removes the requirement that a health care practitioner apply for a separate waiver through the Drug Enforcement Administration (DEA) to dispense certain narcotic drugs (e.g., buprenorphine) for maintenance or detoxification treatment (i.e., substance use disorder treatment). Further, a community health aide or community health practitioner may dispense certain narcotic drugs for maintenance or detoxification treatment without registering with the DEA if the drug is prescribed by a health care practitioner through telemedicine. It preempts state laws related to licensure for this activity. The bill also directs the Substance Abuse and Mental Health Services Administration to conduct a national campaign to educate health care practitioners and encourage them to integrate substance use disorder treatment into their practices.

Lymphedema Treatment Actof 2019 This bill includes certain lymphedema compression treatment items as covered durable medical equipment under Medicare. (Lymphedema is a condition of localized fluid retention and tissue swelling that is caused when the lymphatic system is damaged or blocked.)

Chronic Kidney Disease Improvement in Research and Treatment Act of 2019 This bill addresses Medicare coverage for and access to treatment for chronic kidney disease. Specifically, the bill modifies provisions related to coverage by (1) allowing certain Medicare beneficiaries who have End Stage Renal Disease to enroll in Medicare supplemental policies, and (2) establishing new Medicare payment structures for renal dialysis services. Among other changes, the bill (1) provides for alternative payment methodologies for certain new drugs, biologics, and devices that are renal dialysis services; (2) revises quality measures; (3) establishes an incentive payment methodology; and (4) increases access to kidney disease education services. In addition, the bill requires information sharing between hospitals and renal dialysis centers in some circumstances as well as federal studies on issues related to kidney disease, including the use of palliative care and ways to increase transplantation rates. The Department of Health and Human Services may also award National Health Services Corps scholarships and loan repayment to nephrology health professionals.

Grants for Rural Efforts to Address Treatment and Ensure Recovery in Communities Act of 2020 or the GREATER Communities Act This bill expands efforts to address opioid use in rural areas, including by authorizing the Department of Justice to award grants for pilot programs to provide alternatives to incarceration and reduce opioid overdose deaths.

Examining Opioid Treatment Infrastructure Act of2019 This bill requires the Government Accountability Office to report on inpatient and outpatient treatment capacity, availability, and needs across the United States. The report must include information relating to detoxification programs, clinical stabilization programs, transitional residential support services, rehabilitation programs, treatment programs for pregnant women or adolescents, and treatment through Indian health programs. The report must also include information about the barriers to real-time reporting of drug overdoses at the federal, state, and local levels and ways to overcome those barriers.